TLDR Barclays upgraded Alvotech from Underweight to Overweight, doubling its price target from $4 to $8 The FDA closed its inspection of Alvotech’s Iceland facility...
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. AcceptRead More
